Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Author:

Monin Leticia,Laing Adam G,Muñoz-Ruiz Miguel,McKenzie Duncan R,del Molino del Barrio Irene,Alaguthurai Thanussuyah,Domingo-Vila Clara,Hayday Thomas S,Graham Carl,Seow Jeffrey,Abdul-Jawad Sultan,Kamdar Shraddha,Harvey-Jones Elizabeth,Graham Rosalind,Cooper Jack,Khan Muhammad,Vidler Jennifer,Kakkassery Helen,Sinha Shubhankar,Davis Richard,Dupont Liane,Francos Quijorna Isaac,O'Brien-Gore Charlotte,Lee Puay Ling,Eum Josephine,Conde Poole Maria,Joseph Magdalene,Davies Daniel,Wu Yin,Swampillai Angela,North Bernard V,Montes Ana,Harries Mark,Rigg Anne,Spicer James,Malim Michael H,Fields Paul,Patten Piers,Di Rosa Francesca,Papa Sophie,Tree Timothy,Doores Katie J,Hayday Adrian C,Irshad Sheeba

Funder

Cancer Research UK

Publisher

Elsevier BV

Subject

Oncology

Cited by 509 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3